BioMed Central by Andrew Rl Medford et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
Respiratory Research
Open Access Research
Vascular Endothelial Growth Factor (VEGF) isoform expression 
and activity in human and murine lung injury
Andrew RL Medford1, Samantha K Douglas1, Sofia IH Godinho1, 
Kay M Uppington1, Lynne Armstrong1, Kathleen M Gillespie1, Berendine van 
Zyl1, Terry D Tetley2, Nassif BN Ibrahim3 and Ann B Millar*1
Address: 1Department of Clinical Science at North Bristol, University of Bristol Paul O'Gorman Lifeline Centre, Southmead Hospital, Westbury-
on-Trym, Bristol, BS10 5NB, UK, 2Lung Cell Biology, National Heart & Lung Institute, Imperial College, Dovehouse Street, London, SW3 6LY, UK 
and 3Department of Pathology, North Bristol NHS Trust, Frenchay Hospital, Frenchay Park Road, Frenchay, Bristol, BS16 1LE, UK
Email: Andrew RL Medford - andrewmedford@hotmail.com; Samantha K Douglas - samantha.douglas@bristol.ac.uk; 
Sofia IH Godinho - sofia.godinho@bristol.ac.uk; Kay M Uppington - kay.uppington@bristol.ac.uk; 
Lynne Armstrong - lynne.armstrong@bristol.ac.uk; Kathleen M Gillespie - K.M.Gillespie@bristol.ac.uk; Berendine van 
Zyl - Berendine.vanZyl@bristol.ac.uk; Terry D Tetley - t.tetley@imperial.ac.uk; Nassif BN Ibrahim - Nassif.Ibrahim@nbt.nhs.uk; 
Ann B Millar* - Ann.Millar@bristol.ac.uk
* Corresponding author    
Abstract
Background: The properties of vascular endothelial growth factor (VEGF) as a potent vascular
permogen and mitogen have led to investigation of its potential role in lung injury. Alternate spliced
VEGF transcript generates several isoforms with potentially differing functions. The purpose of this
study was to determine VEGF isoform expression and source in normal and ARDS subjects and
investigate the expression and regulation of VEGF isoforms by human alveolar type 2 (ATII) cells.
Methods: VEGF protein expression was assessed immunohistochemically in archival normal and
ARDS human lung tissue. VEGF isoform mRNA expression was assessed in human and murine lung
tissue. Purified ATII cells were cultured with proinflammatory cytokines prior to RNA extraction/
cell supernatant sampling/proliferation assay.
Measurements and Main Results: VEGF was expressed on alveolar epithelium, vascular
endothelium and alveolar macrophages in normal and ARDS human lung tissue. Increases in VEGF
expression were detected in later ARDS in comparison to both normal subjects and early ARDS
(p < 0.001). VEGF121, VEGF165 and VEGF189 isoform mRNA expression increased in later ARDS (p
< 0.05). The ratio of soluble to cell-associated isoforms was lower in early ARDS than normal
subjects and later ARDS and also in murine lung injury. ATII cells constitutionally produced VEGF165
and VEGF121 protein which was increased by LPS (p < 0.05). VEGF165 upregulated ATII cell
proliferation (p < 0.001) that was inhibited by soluble VEGF receptor 1 (sflt) (p < 0.05).
Conclusion: These data demonstrate that changes in VEGF isoform expression occur in ARDS
which may be related to their production by and mitogenic effect on ATII cells; with potentially
significant clinical consequences.
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Introduction
Functional and physical failure of the alveolar capillary
membrane is a pivotal event in the development of lung
injury, exemplified by the acute respiratory distress syn-
drome (ARDS)[1]. The characteristics of vascular endothe-
lial growth factor (VEGF), as both an angiogenic and
permogenic factor has led to interest in its potential role
in this condition[2,3]. It is known that VEGF protein is
compartmentalized within the lung[4] and alveolar type 2
epithelial (ATII) cells have been identified as a major
source of VEGF in both animal studies and human foetal
lung studies[5,6]. Observational data show plasma VEGF
levels rise and intrapulmonary (ie, measurable in the epi-
thelial lining fluid (ELF) obtained by broncho-alveolar
lavage) levels fall in the early stages of lung injury with
normalization of both during recovery[7,8]. These
changes in intrapulmonary VEGF have been confirmed in
ARDS but have also been observed in other conditions in
which alveolar injury may occur, such as high-altitude
pulmonary oedema [9-11]. To explore the significance of
these observations, it is necessary to understand the mech-
anisms that regulate VEGF bioactivity.
Alternative splicing of the VEGF transcript from exons 5 to
8 leads to the generation of several different isoforms with
variable diffusibilities depending on their length:
VEGF121, VEGF165, VEGF189 being the main forms[3,12-
14]. Exon 6 (not present in VEGF121 and VEGF165) and
exon 7 provide heparin-binding affinity, exon 8 (present
in all active isoforms) is necessary for the stimulation of
mitosis[15]. The longer isoforms are highly basic and
remain virtually completely cell-associated, whereas
VEGF121 (lacking both exons 6 and 7) is freely diffusi-
ble[14]. VEGF165 (lacking exon 6 but not 7) possesses
intermediary properties being largely soluble but a dis-
tinct fraction remains cell-associated[14]. It is the pre-
dominant isoform and most biologically active in the
physiological state[15].
Recovery from lung injury/ARDS requires functional/
physical repair of the alveolar epithelial surface to occur.
ATII cells proliferate and differentiate into alveolar epithe-
lial type 1 (ATI) cells to regenerate the alveolar epithelium
after injury[16]. Limited and conflicting data exists on the
effect of VEGF on alveolar epithelial proliferation; fetal
human lung cells[17,18] and pulmonary adenocarci-
noma derived cell lines proliferate[19], whereas adult rat
ATII cells do not[20]. There are no similar studies of adult
human lung epithelial cells.
We initially hypothesised that changes in VEGF intrapul-
monary levels observed by ourselves and others would be
reflected in whole lung tissue and associated with changes
in VEGF isoforms in ARDS lung which differ in early and
late stages of the disease. We further hypothesised that the
role of VEGF in the lung may be as an epithelial mitogen
integral to lung repair. We have explored this hypothesis
and additionally considered the effects of known inflam-
matory mediators, previously suggested to be involved in
the pathogenesis of ARDS, in these processes.
Methods
Specimens
Archival normal and ARDS lung tissue sections and paraf-
fin blocks for which consent for research had been
obtained, were utilized for immunohistochemistry (ARDS
had been histopathologically confirmed and groups
divided into either "early ARDS" within 48 hours or "later
ARDS" after day 7). ARDS had been diagnosed according
to the internationally used 1994 American-European
Consensus Conference criteria[21]. Isolation of ATII cells
was undertaken from macroscopically normal lung tissue
sections (15 × 5 × 5 cm approximately) were donated by
13 patients (5 females and 8 males) undergoing lobar
resection for malignancy. The median age was 71. Ethical
approval was obtained from the North Bristol and United
Bristol Healthcare Trusts.
Immunohistochemistry for VEGF
Normal, early ARDS and later ARDS lung tissue sections
were examined (n = 8 for each group). Normal lung tissue
implied that there was no lung involvement in the cause
of death. Paraffinised 4 μm sections were de-waxed in
serial xylene (BDH Laboratory Supplies, Poole, UK),
dehydrated in absolute ethanol (BDH Laboratory Sup-
plies, Poole, UK) and pressure cooked in 0.01 M tri-
sodium citrate (BDH Laboratory Supplies, Poole, UK)
buffer (pH 6) to facilitate antigen retrieval. Endogenous
peroxidase was blocked with 3% hydrogen peroxide
(BDH Laboratory Supplies, Poole, UK) in methanol
(BDH Laboratory Supplies, Poole, UK). Sections were
incubated in 2.5% horse blocking serum (Vectastain Uni-
versal Quick Kit, Vector Laboratories, Peterborough, UK)
prior to Avidin D and Biotin blocking sera (Vector Labo-
ratories, Peterborough, UK). A rabbit polyclonal antibody
to VEGF Autogen Bioclear, UK Ltd, Wiltshire, UK) and iso-
typic rabbit IgG controls (Vector Laboratories, Peterbor-
ough, UK) were used. Isotypic control antibodies were
used on normal, early ARDS and later ARDS tissues. The
samples were then stained with pan-specific biotinylated
antibody, streptavidin-peroxidase complex with diami-
nobenzidine substrate (Vectastain Universal Quick Kit,
Vector Laboratories, Peterborough, UK), counterstained
in haematoxylin (BDH Laboratory Supplies, Poole, UK).
Image capture and semi-quantitative densitometry were
achieved using Histometrix version 6 software version 1.4
(Kinetic Imaging) linked to a JVC TK-C1360B camera with
a resolution of 470 TV lines. Pixels representing immuno-
positivity were chosen and this threshold was memorised
by the software. Anything within the selected pixel range
was accounted for and expressed as a percentage of theRespiratory Research 2009, 10:27 http://respiratory-research.com/content/10/1/27
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pixels in the selected area. This gave a composite intensity
score per unit area derived from the staining intensity
value divided by the staining cross-sectional area assessed.
Densitometry was performed on all slides from the same
procedure assigning the same random coloration as unit
of intensity on each slide. Five randomly chosen (compu-
ter generated) areas on each section for each patient were
assessed giving twenty values. Densities on negative con-
trol sections were subtracted from positively stained sec-
tion densities to control for differing background pixel
intensities detected.
Formalin-fixed paraffin embedded (FFPE) RNA extraction 
and measurement
This method is a modified version of the Krafft tech-
nique[22]. Briefly, 8 × 6 μm sections were cut on a micro-
tome from formalin-fixed paraffin-embedded (FFPE)
blocks of archival normal, "early" (within 48 hours) and
"later" ARDS (after day 7) lung tissue. Sections were de-
waxed and washed in Histoclear II and absolute ethanol.
Sections were then dried at 55°C for 3 minutes before
being digested for 6 hours in digest buffer (1 mg/ml pro-
teinase K, 20 mM Tris, 20 mM EDTA buffer at pH 7.4, 1%
SDS) at the same temperature. After ice cooling, RNA was
extracted using phenol:chloroform:isoamyl ethanol mix-
ture before precipitation in sodium acetate, washing and
pelleting.
Animal model of lung injury
Male C57BL/6 mice (18–20 g) were used in a LPS induced
model of lung injury. The experiments were done in
accordance with Home Office guidelines. Briefly mice
were exposed to intranasal LPS (Sigma, Poole, UK; sero-
type 011:B4) dissolved in pyrogen-free saline. Animals
were lightly anaesthetised by placing in a vapour-filled
chamber with halothane (Merial Animal Health). While
anaesthetised, intranasal inoculation of 50 μl of 10 μg
LPS/mouse was performed. This procedure was repeated
daily for 4 days. Control animals were treated with the
same volume of pyrogen-free saline. Animals were sacri-
ficed by halothane hyperanaesthesia and exsanguinated
by cardiac puncture. The lungs were removed, inflated
and snap frozen at day 2 and day 5 post initial LPS insult,
24 hours after last LPS dose. A minimum of n = 4 individ-
ual specimens was utilized in each experiment. Lung
injury was confirmed by histological analysis and RNA
extracted as previously described[23]. Quantitative real-
time PCR was undertaken in the day 5 post LPS mice only.
Isolation and purification of ATII cells
ATII cells were purified according to the method of With-
erden et al[24] as previously described. Sections were per-
fused with 0.9% saline, digested with 0.25% trypsin
(Sigma, Poole, UK) and minced with newborn calf serum
(NCS) (Invitrogen, Paisley). DNAse I was added to the
suspension at 250 μg/ml in 7 ml Hanks Balanced Salt
Solution (HBSS). The suspension was shaken before filter-
ing through a ~500 μm filter and then 40 μm mesh (Fahr-
enheit, Milton Keynes). ATII cells were purified by
differential adhesion. The non-adherent cells were centri-
fuged at 300 g for 10 minutes at 4°C and resuspended at
1 × 106 ATII cells/ml in complete media and put into 60
mm dishes (Greiner Cell Star, Stonehouse) pre-coated
with Vitrogen-100 (Cohesion Technologies, Palo Alto,
USA). The ATII cells were subsequently adhered at 37°C
for 24 hours. The medium and any remaining contami-
nating cells were removed and fresh complete medium
added. The cells were incubated for 16 hours, the medium
removed and the cells washed with HBSS. Fresh complete
medium was added and the cells incubated for a further
24 hours to establish confluent monolayers with ATII cell
morphology confirmed as previously described[24]. ATII
cell phenotype was confirmed by positive staining for
alkaline phosphatase and mRNA transcripts for SP-C and
aquaporin-3. Morphological characteristics were con-
firmed by electron microscopy. ATI cell phenotype was
excluded by negative staining for aquaporin-5.
Purified cells were then either cultured with the pro-
inflammatory agents LPS (10 μg/ml), TNF-α (10 ng/ml),
IL-1b (1 ng/ml) for 4 hours prior to RNA extraction and/
or sequential cell culture supernatant sampling or used in
the proliferation assays described below. A minimum of
10 subject samples were used for each experiment. In vitro
these cells rapidly differentiate and this precludes a pro-
longed culture timepoint.
VEGF isoform-specific RT-PCR
Human and murine RNA was extracted using TRIzol rea-
gent. Reverse transcription (RT) was carried out using the
Superscript II system (Invitrogen). Beta2-microglobulin
(B2M) was used as a housekeeping gene. Amplifications
were carried out in a 20 μl reaction volume containing 13
μl RNase free water, 1.2 μl 25 mM MgCl2 (final concentra-
tion 1.5 mM) (Abgene), 0.4 μl 25 μM dNTPs (Abgene), 1
μl of 20 μM forward and reverse primers, 2 μl 10× reaction
buffer (Abgene) and 0.4 μl 5 U/μl Taq DNA polymerase
(Abgene). The following PCR conditions were used: dena-
turation at 94°C for 3 minutes, annealing at 72°C for 30
seconds then denaturation at 94°C for 30 seconds. The
coding sequences for human VEGF (accession no.
NM_000493, NM_001844, and NM_000088, respec-
tively) and murine VEGF (MN_00441242 for mouse
VEGF) were used to design primers using the online soft-
ware, Primer3 (Whitehead Institute for Biomedical
Research, Cambridge, MA). The primers span intronic
junctions to avoid the amplification of genomic
sequences. Primer sequences used were as in Table 1.
Amplified products were visualized by gel electrophoresis
using ethidium bromide (Sigma, Poole, UK) on a transil-
luminator (BioRad, Hertfordshire, UK) using semi-quan-
titative densitometric analysis (Biorad Geldoc software).Respiratory Research 2009, 10:27 http://respiratory-research.com/content/10/1/27
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Control reactions were run without the addition of reverse
transcriptase. Previous experiments had determined the
RT-PCR data would be in linear phase at a cycle number
of 35 indicating the data were truly semi-quantitative. The
inter-assay variability of densitometry measurements was
11.2%.
Quantitative real-time RT-PCR
Quantitative real-time RT-PCR for VEGF isoforms was per-
formed in a 25 μl reaction volume containing 12.5 μl of
the SYBR Green PCR master mix (Sigma, Poole, UK), 5 μl
of the RT reaction mixture, and 300 nM each primer using
the Smart Cycler II System (Cepheid, Sunnyvale, CA). A
standard curve was generated for each test mRNA using 8
serial dilutions from neat RNA to 1:200,000. The amplifi-
cation program consisted of initial denaturation at 95°C
for 2 minutes followed by 40 cycles of 95°C for 15 sec-
onds, annealing at 58°C for 30 seconds, and extension at
72°C for 15 seconds. Primer sequences were as in Table 2.
Commercially available GAPDH primers were used http:/
/www.primerdesign.co.uk and used as a reference for nor-
malization in all RT-polymerase chain reactions (RT-
PCRs).
VEGF ELISA
Cell culture supernatants were assayed for VEGF
(VEGF121, VEGF165 only) using a commercial ELISA kit
(R&D Systems). In brief, a specific monoclonal antibody
was coated onto a microplate. Standards and samples
were added and a polyclonal detection antibody added.
The resultant colour developed in proportion to the
amount of growth factor present and was read spectro-
photometrically. The detection limit was 3 pg/ml.
Cell Proliferation Assay (3H-thymidine incorporation)
ATII cells were seeded in 24-well plates (Greiner bio-one
Ltd, Stonehouse, UK) in complete medium (10%NCS/
DCCM/1% penicillin/streptomycin/amphotericin B)
(Sigma, Poole, UK) at 100,000 cells per well. For 48 hours
the cells were incubated in 5 ng/ml VEGF165 ± 10 ng/ml
sflt, 10 ng/ml KGF (as a positive control) and 10 ng/ml sflt
(as a specific VEGF inhibitor) alone. The concentrations of
KGF and sflt correspond to previously published concen-
trations in primary cell studies. 5 ng/ml VEGF165 approxi-
mates to epithelial lining fluid concentrations of VEGF in
normal subjects and also following recovery from
ARDS[4,8]. The cells were then washed with HBSS (Sigma,
Poole, UK) and incubated in complete medium. Recom-
binant proteins and 37 kBq methyl-[3H] thymidine
(Amersham Biosciences) were added to each well. At 48
hours incubation at 37°C, the cells were washed with
trichloracetic acid 5% in PBS and then solubilized by add-
ing 0.5 ml of 0.3 M NaOH (Sigma, Poole, UK). Cell lysates
were subsequently pipetted into scintillation vials (Fisher
Scientific UK Ltd, Loughborough, Leicestershire, UK) con-
taining 2 mls of scintillation liquid (Amersham Bio-
sciences) and counted by a β-counter; Beckmann
Instruments (Beckman Coulter Ltd, High Wycombe,
Buckinghamshire, UK).
Cell count
ATII were seeded in 24-well plates (Greiner Bio-one Ltd,
Stonehouse, UK) in complete medium, at 100,000 cells
per well. After 48 hours, cells were washed with HBSSS
and the protein of interest added. After 48 hours incuba-
tion, cells were washed with PBS and incubated with 100
μl of Trypsin-EDTA (Sigma, Poole, UK). When the cells
Table 1: Table of primer sequences for semi-quantitative RT-PCR for human VEGF and beta-microglobulin (B2M)
RT-PCR Product sense antisense
human VEGF121,165,189 5'-GAGATGAGCT TCCTACAGCAC-3' 5'-TCACCGCCTCGGCTTGTCACAT-3'
B2M 5'-GCATCATGGAG GTTTGAAGATG-3 5'-TAAGTTGCCAG CCCTCCTAGAG-3'
Table 2: Table of primer sequences for quantitative real time PCR (QPCR) for human and murine VEGF
QPCR Product sense antisense
human VEGF165 5'-ATCTTCAAGCCATCCTGTGTGC-3' 5'-CAAGGCCCACAGGGATTTTC-3'
human VEGF189 5'-ATCTTCAAGCCATCCTGTGTGC-3' 5'-CACAGGGAACGCTCCAGGAC-3'
murine VEGF120 5'-AACGATGAAGCCCTGGAGTG-3' 5'-TGAGAGGTCTGGTTCCCGA-3'
murine VEGF164 5'-AACGATGAAGCCCTGGAGTG-3' 5'-GACAAACAAATGCTTTCTCCG-3'
murine VEGF188 5'-AACGATGAAGCCCTGGAGTG-3' 5'-AACAAGGCTCACAGTGAACG-3'Respiratory Research 2009, 10:27 http://respiratory-research.com/content/10/1/27
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were unattached, 100 μl of culture medium containing
10% FBS was added. Cells were then counted under the
microscope using a haemocytometer.
Statistics
Data were analyzed by ANOVA with Bonferroni post hoc
multiple comparison correction using GraphPad Prism
version 4.0 software. A p value of < 0.05 was considered
significant.
Results
Human VEGF lung expression and quantification in 
normal, early and late ARDS
Human VEGF expression was noted on alveolar epithe-
lium and macrophages with weaker endothelial expres-
sion in all human tissue sections. VEGF expression was
significantly increased in late ARDS compared to both
normal subjects and early ARDS (p < 0.001) (Figure 1).
This represented all VEGF isoforms both soluble and
membrane-bound.
Human VEGF isoform RT-PCR in normal, early and late 
ARDS
In order to determine the individual VEGF isoforms, RT-
PCR was initially used. A representative RT-PCR gel from
the human FFPE tissue is shown in Figure 2a. When indi-
vidual isoforms were compared between groups, a signif-
icant increase in all three isoforms was detected in later
versus early ARDS (p < 0.05) as seen in Figure 2b–d. How-
ever, when considering individual relative isoform pro-
duction in disease there was a significant decrease in the
relative ratio of soluble to cell-associated isoforms in early
ARDS (p < 0.05) as seen in Figure 2e (comparing com-
bined densitometry data).
Murine VEGF mRNA expression
The human samples used were of archival post-mortem
origin and hence potentially subject to post mortem deg-
radation although a recent study suggests that this is min-
imal[25]. In order to support these human findings, we
repeated the mRNA analysis in samples extracted from
snap frozen murine whole lung injury samples. We dem-
onstrated a significant fold increase in all isoforms (p <
0.05) (Figure 3). Analysis of absolute values showed a sig-
nificantly greater amount of VEGF188 than VEGF164 and
VEGF120 (p < 0.05).
ATII VEGF mRNA isoform expression (RT-PCR)
The main source of VEGF on the basis of our immunocy-
tochemistry results were ATII cells so we isolated these for
further investigation. We found that ATII cells constitu-
tively express mRNA for all the three main VEGF isoforms:
VEGF121, VEGF165 and VEGF189 (Figure 4a). All isoforms
were significantly increased in comparison to control fol-
lowing treatment with 10 ng/ml VEGF165 (p < 0.05 for
VEGF165, p < 0.01 for other isoforms) and 10 μg/ml LPS
A) Immunocytochemistry of human whole lung tissue (× 40) showing (A) isotypic control (from later ARDS), (B) normal con- trols, (C) early ARDS, (D) later ARDS (magnification × 40) Figure 1
A) Immunocytochemistry of human whole lung tissue (× 40) showing (A) isotypic control (from later ARDS), 
(B) normal controls, (C) early ARDS, (D) later ARDS (magnification × 40). Immunostaining shows positive VEGF 
expression in alveolar epithelium (AE), alveolar macrophages (AM) and (to a lesser extent) vascular endothelium (VE). Signifi-
cant increase in staining noted in ARDS, especially later ARDS. Staining was assessed semiquantitatively using Histometrix soft-
ware analysis. B) Histometric analysis of human VEGF in healthy human lung, early and later ARDS. *P < 0.001 in later ARDS 
versus early ARDS and normal, (ANOVA with post-hoc Bonferroni). Data are normal and plotted as mean and standard error.
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A): Representative RT-PCR gel for human VEGF isoforms in normal, early and later ARDS, lanes as follows: (1) early ARDS, (2)  later ARDS, (3) negative control, (4,5,6) sequenced positive controls (VEGF121, VEGF165 and VEGF189 respectively), (7) 100 kb  ladder (bottom marker denotes 100 bp, top marker 300 bp) Figure 2
A): Representative RT-PCR gel for human VEGF isoforms in normal, early and later ARDS, lanes as follows: 
(1) early ARDS, (2) later ARDS, (3) negative control, (4,5,6) sequenced positive controls (VEGF121, VEGF165 
and VEGF189 respectively), (7) 100 kb ladder (bottom marker denotes 100 bp, top marker 300 bp). B-E): Semi-
quantitative densitometry of (B) VEGF189, (C) VEGF165, (D) VEGF121 relative to β-microglobulin (B2M) in normal, early and later 
ARDS (*p < 0.05 late versus early ARDS), (E) ratio of soluble (VEGF121, VEGF165) to cell-associated (VEGF189) isoforms (*p < 
0.05 early versus normal and later ARDS). Data are plotted as means with bars denoting standard errors (ANOVA with post-
hoc Bonferroni) for B-E).
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4 samples were examined for each treatment group Figure 3
4 samples were examined for each treatment group. A) Representative RT-PCR gel of VEGF isoforms in control and 
injured murine lung. Lanes are as follows: (1–8) injured murine lung at day 5 (24 hours post last LPS dose) (9–12) injured 
murine lung at day 2 (24 hours post last LPS dose), (13–14) control murine lung. B-D): Further real-time PCR analysis was 
undertaken in the samples at day 5. This confirmed the increased levels of VEGF120, VEGF164 and VEGF188 in injured murine 
lung (*p < 0.05 fold change compared to control).
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A) Representative RT-PCR gel of VEGF isoforms in ATII cells Figure 4
A) Representative RT-PCR gel of VEGF isoforms in ATII cells. Lanes are as follows: (1–4) human ATII cell samples, (5) 
blank, (6) negative control, (7–9) sequenced positive controls for VEGF121, VEGF165 and VEGF189 respectively, (10) 100 kb lad-
der (bottom marker denotes 100 bp, top marker denotes 300 bp). B-D): Semiquantitative densitometry data (n = 8, in tripli-
cate) showing VEGF121, VEGF165and VEGF189 in response to LPS (10 μg/ml), TNF-α (10 ng/ml), IL-1β, VEGF165 (0.1,1,10 ng/ml) 
at 4 hours. Data are plotted as mean with bars denoting standard error. *P < 0.05 (ANOVA post hoc Bonferroni) 10 μg/ml LPS 
versus control (all isoforms) and 10 ng/ml VEGF165 versus control (VEGF165 only). #P < 0.01 (ANOVA, post hoc Bonferroni) 10 
ng/ml VEGF versus control (VEGF121 and VEGF189). E-F): Further real-time PCR analysis confirmed the effect of LPS and VEGF 
on VEGF165 and VEGF189 (*p < 0.05 fold change compared to control).
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(p < 0.05) at 4 hours (Fig 4b–d). Other pro-inflammatory
stimuli (TNF, IL-1) and lower concentrations of VEGF165
did not alter relative VEGF isoform expression. These
results were confirmed by Q-PCR showing a doubling of
VEGF189 and VEGF165 compared to control (p < 0.05) in
response to LPS 10 μg/ml and VEGF 10 ng/ml (Figure 4e–
f).
ATII VEGF protein levels and response to LPS
Having determined the production of VEGF isoforms at
the mRNA level we went on to assess the release of the sol-
uble isoforms (VEGF121, VEGF165) by the cultured cells.
ATII cells express significant amounts of VEGF121 and
VEGF165  constitutively (Figure 5). These levels signifi-
cantly increased with time in human ATII supernatant (p
< 0.01 vs control at 24 hours). At 24 hours, LPS (100 ng/
ml) further stimulated VEGF production (p < 0.05).
ATII proliferation
Having determined the production of VEGF by the ATII
cell population, we explored the potential effect of
VEGF165 on these cells. An increase in human ATII cell
proliferation as assessed by 3H-thymidine was detected
with 5 ng/ml VEGF165 (p < 0.001), comparable to levels
detected previously in bronchoalveolar lavage fluid[8]).
Furthermore, with the addition of a natural VEGF inhibi-
tor, soluble VEGFR1 (sflt), there was a significant reduc-
tion in proliferation compared to serum control (p <
0.05) suggesting an autocrine effect (Figure 6). The addi-
tion of sflt  alone and in combination with VEGF165
showed no significant difference in cell number compared
to serum control (p > 0.05) but did significantly inhibit
VEGF165-induced increase in cell number (p < 0.001 com-
pared to 5 ng/ml VEGF165). This suggested that VEGF165
was inducing proliferation rather than survival alone.
Discussion
Previous observational data by ourselves and others have
demonstrated plasma VEGF levels rise and intrapulmo-
nary levels fall in the early stages of lung injury with nor-
malization of both during recovery[7,8]. Similarly,
reduced levels of VEGF have been described in normal
smokers and patients with idiopathic pulmonary fibrosis
(IPF); other conditions in which damage to the alveolar
epithelium may be present[26].
Potential explanations for the apparent reduction in
intrapulmonary VEGF levels in early ARDS are manifold
and not mutually exclusive. They include increased mem-
brane-bound rather than soluble isoforms, changes in iso-
form expression and damage to the alveolar-capillary
membrane with consequent leakage of intrapulmonary
VEGF into the vascular bed [27-30].
We therefore assessed expression of VEGF and its specific
isoforms by immunohistochemistry and isoform-specific
RT-PCR (as isoform-specific antibodies are not available)
in archival normal and ARDS lung tissue. We demon-
strated a significant up-regulation of VEGF in later ARDS
tissue compared to normal subjects. However in early
ARDS, in contrast to our epithelial lining fluid (ELF) find-
ings we did not detect a reduction in total VEGF expres-
sion[8]. One other group has also explored this area, but
using different timepoint characteristics, whole tissue
homogenates including inflammatory cells and did not
assess differential isoform expression[11]. In both these
studies ELISA methodology was used which detects only
the soluble isoforms, VEGF121 and VEGF165[8].
In order to consider changes in isoform expression as a
possible explanation for these discrepancies, we assessed
mRNA as there are no isoform-specific antibodies cur-
rently. No significant reduction in VEGF isoform expres-
sion occurred in early ARDS in comparison to normal
subjects although a trend was suggested. However, signif-
icant changes were detected between early and later ARDS
in all isoforms and there was a significant decrease in the
relative ratio of soluble to cell-associated isoforms in early
ARDS compared to later ARDS and normal subjects. In the
context of our previous ELF findings, this data is support-
ive of the suggestion that isoform switching is a critical
regulatory mechanism for VEGF bioactivity in that iso-
form-specificity may be important in ligand-VEGF recep-
tor interactions[31]. Furthermore, there is more potential
for soluble VEGF to have extrapulmonary effects which is
extremely relevant since the most common cause of death
in ARDS is multi-organ system failure[32,33].
Obtaining ARDS lung tissue is limited by the lack of sur-
gical biopsies of this disease in our clinical practice and
theoretically necropsy lung tissue might introduce selec-
ATII cell supernatant levels of VEGF protein significantly  increases with time in unstimulated cells, unstimulated cell  supernatants control v 24 hrs, filled bars, (#p < 0.01) with a  significant increase in response to LPS 100 ng/ml at 24 hours,  unfilled bars, (*p < 0.05), ANOVA with post hoc Bonferroni Figure 5
ATII cell supernatant levels of VEGF protein signifi-
cantly increases with time in unstimulated cells, 
unstimulated cell supernatants control v 24 hrs, filled 
bars, (#p < 0.01) with a significant increase in 
response to LPS 100 ng/ml at 24 hours, unfilled bars, 
(*p < 0.05), ANOVA with post hoc Bonferroni.
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tion bias for a more severe spectrum of ARDS, as intrapul-
monary VEGF levels are known to be lower in non-
survivors with ARDS[8]. There was no evidence of any sig-
nificant lung disease in the normal necropsy lung tissue,
but it is conceivable that the extra-pulmonary disease
process contributing to death might have affected VEGF
levels although recent data suggests this is not the
case[25]. In order to investigate this possibility we
repeated this analysis in snap frozen lung tissue from our
multiple dose LPS-induced lung injury model at day 5
post initial injury, reflecting early ARDS [23]. These data
supported the human post mortem findings of an increase
in cell-associated VEGF in an ARDS situation.
Previous in vitro studies had confirmed VEGF is abundant
in lung and suggested the alveolar epithelium as a key
source [5,6,34]. Several lines of in vitro evidence have
pointed to a possible role for VEGF in lung repair and
recovery following injury[19,29,35,36]. In one LPS-
induced murine model of lung injury, intrapulmonary
levels of VEGF increased following injury for 96 hours,
mirroring the increase in bronchoalveolar lavage fluid
protein and neutrophils with significant VEGF localiza-
tion to lung epithelium but increases mainly in inflamma-
tory cells [37]. However, previous experiments performed
in our laboratory have confirmed pg/ml levels of expres-
sion of VEGF in cultured alveolar macrophage superna-
tants from patients with ARDS and "at risk" of ARDS
suggesting that they are unlikely to be the main cellular
source of VEGF, although they may contribute [8]. In both
newborn and adult rabbit, hyperoxic lung injury resulted
in a relative reduction in VEGF189 and parallel increase in
VEGF121 and VEGF165 mRNA expression with normaliza-
tion to control values during recovery[38]. Therefore, we
went on to investigate the role of human ATII cells as both
a source and potential target for VEGF bioactivity.
We initially established at the mRNA level that ATII cells
express the major VEGF isoforms (VEGF121,165) (both sol-
uble) and VEGF189 (membrane-associated). The specific
functions of these isoforms have not been clearly identi-
fied in humans although genetically modified mouse
models suggest they may be significant. Ideally, we would
have isolated ATII cells from ARDS lung biopsies and
undertaken mRNA analysis but this was not possible as
described above. We have also shown that VEGF165 is dif-
ferentially upregulated by various exogenous compounds,
in particular LPS.
Bar graphs depicting 3H-thymidine incorporation into ATII cells (A) and cell number (B) following treatment for 48 hours with  VEGF 5 ng/ml, sflt 10 ng/ml and combination confirming a significant proliferation with VEGF 5 ng/ml (#p < 0.001 vs serum con- trol) Figure 6
Bar graphs depicting 3H-thymidine incorporation into ATII cells (A) and cell number (B) following treatment 
for 48 hours with VEGF 5 ng/ml, sflt 10 ng/ml and combination confirming a significant proliferation with VEGF 
5 ng/ml (#p < 0.001 vs serum control). The presence of sflt not only inhibited the proliferative effect of VEGF but also 
reduced proliferation below that of serum controls (*p < 0.05), suggesting an autocrine effect. Cell number also increased sig-
nificantly with 5 ng/ml VEGF165 (**p < 0.01) compared to serum control. The addition of sflt alone and in combination with 
VEGF165 showed no significant difference compared to serum control (p > 0.05) but did significantly inhibit VEGF165-induced 
proliferation (p < 0.001 compared to 5 ng/ml VEGF165).
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We demonstrated for the first time that primary human
ATII cells constitutively produce soluble VEGF
(VEGF121,165) isoforms in a dose-dependent manner that
increased in response to LPS (p < 0.05). This is in agree-
ment with other studies showing high ELF levels in nor-
mal human subjects[4]. The increase in constitutional
production in time would suggest active secretion. The
relationship of these findings at the protein level to those
at the mRNA level is not clear-cut. The ELISA used does
not differentiate between VEGF121 and VEGF165 and only
detects the unbound free protein. Cell-associated VEGF is
not detected and may be considerable.
The high intrapulmonary levels of VEGF and its changes
in ARDS led us to hypothesise that VEGF may be an epi-
thelial mitogen or survival factor. This has particular rele-
vance in repair following injury as occurs in ARDS when
the alveolar epithelial surface must be regenerated to clear
fluid and restore the normal ATI cells and gas
exchange[39]. The evidence for VEGF as an epithelial
mitogen conflicts. Proliferation in human fetal
explants[18] and acid-injured A549 cells[19,40] and sur-
factant production by murine ATII cells[36] have been
described, but these data were not supported when rat
ATII cells were used[20]. In the current study, we have
shown for the first time that VEGF at 5 ng/ml (akin to nor-
mal human ELF VEGF levels), induces significant prolifer-
ation of these cells which is inhibited by the specific
inhibitor sflt. Furthermore, the reduction in proliferation
by the addition of sflt suggests a potential autocrine effect
of this protein.
We have only explored the effects of VEGF165 in this study
and other isoforms may also be relevant. In addition,
sample numbers are limited and subject to biological het-
erogeneity inherent in primary cell studies and our pre-
liminary findings need to be expanded upon and analysed
individually in greater depth using techniques such as
laser capture microdissection for single cell PCR analysis.
VEGF189 can be cleaved in into smaller units. Therefore,
repeating these experiments with a cleavage inhibitor
should be considered in the future. The relevance of this is
that the concept of soluble versus cell-associated isoforms
has not yet been fully resolved and proteolytic cleavage
may alter isoform ratios in ways not detected in this study.
In conclusion, we present evidence that changes in VEGF
isoforms occur between early and late ARDS. These data
are supported by both murine model and isolated human
ATII cell data. We have demonstrated ATII cells to be a
source of VEGF isoforms upregulated by lipopolysaccha-
ride, often implicated in the ARDS process. Finally we
show evidence that VEGF165 is an ATII cell mitogen, induc-
ing proliferation which was inhibited by soluble VEGFR1.
These data suggest a key role for VEGF bioactivity in lung
injury and ARDS.
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